SSelectStock

DCALDishman Carbogen Amcis Limited

Pharma · Biotechnology · NSE · as of 2026-09-11 (delayed ~30 min in market hours)

Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It offers cholesterol and vitamin D analogs; generic active pharmaceutical ingredients for diagnostics, ophthalmic treatments, laxatives, organophosphate antidotes; ammonium, phosphonium; quats, phosphoranes, and wittig reagents; cholesterol and lanolin-related products; sterile injectables; and softgel formulations, as well as hand and body wash, sanitisers, and antiseptics. The company was founded in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.

167.25
0.14%
31Weak

Mkt Cap
₹2,627 Cr
P/E
26.9
P/B
0.5
Div Yield
0.00%
52W High
₹321.95
52W Low
₹128.50

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)2,627.40
P/E26.89
P/B0.45
PEG
ROE %1.56
ROCE %2.30
Debt / Equity0.46
EPS6.22
Revenue Growth %18.90
Profit Growth %-49.50
Dividend Yield %0.00
Promoter Holding %69.30
FII Holding %2.69
DII Holding %
Beta0.62

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

AVOIDConviction 76%

Why avoid

  • Overall evidence is weak (AlgoScore 31/100)
  • Profit growth: -49.5% YoY
  • ROE: 1.6%
  • RSI: 37
  • MACD: bearish
  • Double Top bearish signal (setup quality 59%)

Bull case

  • Revenue growth: 18.9% YoY
  • Debt/Equity: 0.46
  • Promoter holding: 69.3%
  • Sector momentum: sector +6.2% (1m)

Bear case

  • Profit growth: -49.5% YoY
  • ROE: 1.6%
  • RSI: 37
  • MACD: bearish

Key risks

  • Elevated volatility / drawdown profile — size positions accordingly
  • Momentum is fading versus the broader market
  • Profit growth: -49.5% YoY
  • ROE: 1.6%

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)
₹167.25
Stop Loss
₹161.93
risk 3.2%
Target 1 (1.5R)
₹175.22
+4.8%
Target 2 (3R)
₹183.20
+9.5%
Support (20d)
₹163.57
Resistance (52w)
₹321.95
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹5.32/share
ATR (volatility)
₹6.45
avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹6.45). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental46
Technical16
Momentum25
Risk (safety)44

Peers — Pharma

CORONA 1.60%
87
GRANULES 1.12%
81
LAURUSLABS 1.23%
79
KPL 3.75%
79
DIVISLAB 1.23%
79
CAPLIPOINT 1.45%
78